Cerevance to Participate in the 25th Annual Needham Virtual Healthcare Conference

Cerevance to Participate in the 25th Annual Needham Virtual Healthcare Conference

What's a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

‍Boston, MA - April 8, 2026 - Cerevance, a clinical-stage biopharmaceutical company advancing targeted therapies for neurodegenerative diseases and obesity, today announced participation in one-on-one meetings with investors at the 25th Annual Needham Virtual Healthcare Conference being held from April 13-16.

About Cerevance

Cerevance is focused on advancing cell type-specific therapies for the treatment of neurodegenerative diseases and obesity. Our proprietary platform, Nuclear Enriched Transcript Sort sequencing (NETSseq), enables identification of potential drug targets from human brain samples expressed in specific cell types, including those at very low levels or within rare cell populations, and whose expression may change as a disease progresses. Our most advanced investigational treatment, solengepras, is currently in Phase 3 development and has the potential to be a first-in-class, oral non-dopaminergic therapy for both motor and non-motor symptoms of Parkinson's disease. Our second investigational treatment, CVN293, is a highly selective oral inhibitor targeting THIK1 (KCNK13), a two-pore potassium channel family member. CVN293 represents a potentially novel intervention point for neurodegenerative disorders and obesity.

For more information, please visit www.cerevance.com and follow us on LinkedIn and X.

Contacts

Cerevance:

Johnna Simoes, [email protected]

Media

April Dovorany, [email protected]